<DOC>
	<DOC>NCT01861912</DOC>
	<brief_summary>The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.</brief_summary>
	<brief_title>Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Having signed informed consent; Histological or clinical diagnosis of hepatocellular carcinoma（HCC）; The target lesion should had at least one diameter line available for measurement, with the maximum diameter ≥5cm and ≤10cm； Barcelona Clinic Liver Cancer staging B or C; ChildPugh liver function class: score≤7； Eastern Cooperative Oncology Group performance 0 or 1; At least 12 weeks life expectancy; Never received systemic treatment, such as oral molecularly targeted drugs and systemic chemotherapy; Be able to abide by the treatment and followup plan； Adequate results for laboratory tests, including: 1. Neutrophil count≥1.5×109/L, platelet count≥60×109 /L; hemoglobin≥85g/L; 2. Total bilirubin≤51.3 μmol/L, albumin≥28 g/L,and alanine aminotransferase and aspartate aminotransferase≤5 times the upper limit of the normal range; 3. Amylase and lipase≤1.5 times the upper limit of the normal range 4. Serum creatinine≤20 g/L 5. Prothrombin time international normalized ratio ≤1.7; or prothrombin time≤4seconds above control; 6. Left ventricular ejection fraction≥50% according to twodimensional echocardiography; Contraception: during the trail and 12 weeks after the withdrawal, female of childbearing age (WOCBP), WOCBP whose male partners receive study drug or male must use appropriate contraceptive to avoid pregnancy; Disease should be excluded: 1. CT / MRI showed diffuse lesions; 2. Extrahepatic metastasis (metastasis in lungs not included); 3. Invasion in the main portal vein / vena cava or other major vascular; 4. Previous shunt surgery; 5. PreviousTACE or transarterial embolization for HCC, unless there is a untreated lesion; 6. Hepatic encephalopathy in the past or present; 7. Current ascites requiring treatment; Medical history and concomitant diseases: 1. Previous or current cancer other than HCC, unless it is cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1). Cancer having received curative treatment 5 years ago will not be excluded; 2. Disease history in the cardiovascular system as the following: (a)Uncontrolled hypertension；(b)Congestive heart failure in New York Heart Association grade 3 or 4; (c)Active coronary artery disease within 12 months, unstable angina or newly diagnosed angina/myocardial infarction;(d)Arrhythmia requiring drugs other than βblockers and digoxin;(e)Valvular heart disease ≥ CTCAE grade 2； c) Corrected QT interval (Fridericia)&gt; 450 ms confirmed by 2 ECGs in a row d) Thrombotic or embolic events within 6 months, e) Gastrointestinal bleeding within 6 months; f) Unstable and / or active stomach ulcer within 6 months, unless gastroscopy showed it to be fully recovered; g) Variceal bleeding within 6 months; h) Unhealed wound or ulcer, fracture within 3 months; i) Major surgery, open biopsy, or severe trauma within 3 weeks; j) History of organ transplant or subjects in the transplant waiting list; k) Uncontrolled abnormal thyroid function; l) HIV infection; m) Active or untreated hepatitis B; laboratory tests unsuitable for the enrollment： 1. Hyponatremia, serum sodium &lt;130 mmol / L； 2. Hypokalemia, serum potassium &lt;3.5 mmol / L； Allergic reactions to arsenic trioxide and any other drugs used in this trail; Forbidden therapies and/or drugs: 1. Condensation treatment (e.g., warfarin or heparin); 2. Chronic antiplatelet therapy (Aspirin ≥ 300 mg / day; clopidogrel ≥ 75 mg / day); 3. Radiotherapy within 4 weeks;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Carcinoma, Hepatocellular</keyword>
	<keyword>Arsenic trioxide</keyword>
</DOC>